Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOMPENSE: Right Ventricular Compensation with Sotatercept
2024-512543-23-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sotatercept in Plexogenic Pulmonary Arteriopathy and Heritable Pulmonary Arterial Hypertension (HPAH), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in power per beat after 24 weeks of sotatercept and Change in right ventricular pulmonary artery coupling index (Ees/Ea) after 24 weeks of sotatercept. Planned start Apr 2025; status: authorised.
02
Drugs
sotatercept
03
Conditions
Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)
Beyond the preview
Go deeper on 2024-512543-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512543-23-00.